

Hindustan Unilever Limited,
Unilever House,
B D Sawant Marg, Chakala,
Andheri East, Mumbai 400 099

Tel: +91 (22) 50433000 | Web: www.hu.l.co.in | CIN: L15140MH1933PLC002030



Hindustan Unilever Limited

9th November, 2022

Stock Code: BSE-500696

NSE- HINDUNILVR

ISIN: INE030A01027

BSE Limited
Corporate Relationship Department,
2nd Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to the provisions of Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform that the Company had entered into Consignment Selling Agency Agreement(s) ('Agreement') with GlaxoSmithKline Asia Private Limited and GlaxoSmithKline Consumer Private Limited (hereinafter referred to as 'GSKAPL' and 'GSKCPL', respectively) on 1st April, 2020.

This is to further inform that the Company, GSKAPL and GSKCPL have mutually agreed and expressed their intention to terminate the Agreement(s) with effect from 8th November, 2023. As per the Agreement(s), the one-year notice period for termination shall commence from 9th November, 2022.

Hindustan Unilever Limited,
Unilever House,
B D Sawant Marg, Chakala,
Andheri East, Mumbai 400 099

Tel: +91 (22) 50433000 | Web: www.huL.co.in | CIN: L15140MH1933PLC002030



Hindustan Unilever Limited

Disclosure as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is enclosed as per Annexure 1.

We request you to take the same on your record.

Thanking You,

Yours faithfully,

For Hindustan Unilever Limited

Dev Bajpai
Executive Director, Legal & Corporate Affairs
and Company Secretary
DIN: 00050516 / FCS No: F3354
Encl. as above



Annexure-1

Disclosure as per Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015:

Sr. No.	Particulars of Events	Details
1.	Name(s) of parties with whom the agreement is entered;	GlaxoSmithKline Consumer Private Limited and GlaxoSmithKline Asia Private Limited (hereinafter referred to as 'GSKAPL' and 'GSKCPL', respectively), respectively.
2.	Purpose of entering into the agreement;	To enter into an arrangement with with GSKAPL and GSKCPL for promotion, marketing, distribution and selling of the Over-the-Counter and Oral Care products.
3.	Shareholding, if any, in the entity with whom the agreement is executed;	Nil
4.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	-
5.	Whether, the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship;	No
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length";	No
7.	In case of issuance of shares to the parties, details of issue price, class of shares issued;	N.A.



8.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;	N.A.
9.	<p>In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):</p> <p>A) name of parties to the agreement;</p> <p>B) nature of the agreement;</p> <p>C) date of execution of the agreement;</p> <p>D) details of amendment and impact thereof or reasons of termination and impact thereof.</p>	<p>A) GlaxoSmithKline Consumer Private Limited and GlaxoSmithKline Asia Private Limited (hereinafter referred to as 'GSKAPL' and 'GSKCPL', respectively);</p> <p>B) Consignment Selling Agency Agreement;</p> <p>C) 1st April, 2020;</p> <p>D) The Company and GSKAPL GSKCPL companies have mutually agreed and expressed their intention to terminate the Agreement(s) with effect from 8th November, 2023 and the one year notice period of termination shall commence from 9th November, 2022. This shall not have any material effect on the operations of the Company.</p>